> Yes because a core reason fro this technology is evaluation of de-novo designs (small peptide binders; scFvs; sdAbs)
You are not understanding the distinction. OP was speaking about macromolecular complexes, which are explicitly not what the current round of tools are good at. This is not the same as peptides, small molecules or antibody binding.